The GenCRISPR™ Ultra Cas9 product line provides customers with a selection of research use, GMP preclinical and GMP compliant Cas9 nucleases. The Cas9 protein can be formed with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex to perform gene editing has been shown to reduce the challenges encountered with other CRISPR gene editing techniques such as viral and plasmid delivery. Challenges include off-target effects, cell viability and trascprition/translational challenges.
GenCRISPR™ Ultra Cas9 is produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with an N-terminal nuclear localization signal (NLS).
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
Cas9 with an N-terminal NLS expressed by E.coli
Cas9 is active at 37 ℃.
as a solution of 25 mM Tris, 300 mM NaCl,
0.1 mM EDTA, 50% Glycerol pH 8.0 at 25°C.
|Storage||This product remains stable up to 12 months at -20°C. Avoid repeated freeze-thaw cycles.|
efficiencies: Consistent high editing efficiency in in-vitro and in-vivo.
Tag-free: Amino acid is free from additional tagging amino acid.
Animal-free: Plant-based culture media, enzyme-free chromatographic purification.
DNA-free: No external DNA added to the system.
gRNA-dependent double-stranded DNA cleavage
Clear, colorless liquid
≥ 95% as analyzed by SDS-PAGE
≥ 90% as analyzed by SEC-HPLC
|Concentration by A280||
10 mg/ml ± 1 mg/ml
|Bioactivity (in vitro)||
Non-specific DNase activity
Non-specific RNase activity
≤ 10 EU/mg as analyzed by gel clotting method
For more documents, please visit "Technical Support".